ReviewClinical immunology (Orlando, Fla.)2011
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.
Review in Clinical immunology (Orlando, Fla.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 124 citations in OpenAlex.
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias.The Journal of experimental medicine · 2014Trial
- Facts and Hopes of Chimeric Antigen Receptor-Redirected NK T Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Dual regulatory role of natural killer T cells during development of hepatocellular carcinoma.Communications biology · 2025Article
- Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells.Cell reports. Medicine · 2025Article
- Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing.International journal of biological sciences · 2025Review
- Lactylation and antitumor immunity.Frontiers in immunology · 2025Review
- Innate iNKT cells: from biological insight to clinical impact.Frontiers in immunology · 2025Review
- CAR-iNKT cells: redefining the frontiers of cellular immunotherapy.Frontiers in immunology · 2025Review
- Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells.Clinical immunology (Orlando, Fla.) · 2024Review
- Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).Oncogene · 2024Article
- Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.Current pharmaceutical biotechnology · 2024Review
- invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies.Frontiers in transplantation · 2024Review
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy.Cancer cell international · 2023Review
- Advancing cell-based cancer immunotherapy through stem cell engineering.Cell stem cell · 2023Review
- Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes.Frontiers in immunology · 2023Review
- Human iNKT Cells Modulate Macrophage Survival and Phenotype.Biomedicines · 2022Article
- Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors.International journal of molecular sciences · 2022Article
- Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance.International journal of molecular sciences · 2022Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Vα24-invariant natural killer T cells (NKTs) are strictly CD1d-restricted, and CD1d expression has been found in several types of leukemia and lymphoma as well as in brain tumors suggesting that these malignancies could be targeted for direct NKT-cell cytotoxicity. Several studies have revealed strong positive associations between the numbers of tumor-infiltrating or circulating NKTs with improved disease outcome in patients with diverse types of CD1d-negative solid tumors. The mechanism by which NKTs mediate anti-tumor activity against CD1d-negative tumors has long remained enigmatic. Recent evidence indicates that NKTs can suppress tumor growth indirectly by targeting CD1d-positive elements of tumor-supportive stroma such as tumor-associated macrophages. This review summarizes the current knowledge about the mechanisms that regulate NKT-cell localization to the tumor site and their interaction with the tumor microenvironment. The discussed strategies for pharmacologic modulation and genetic engineering of NKTs may lead to development of effective and broadly applicable immunotherapies of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.